Prostate Cancer Program
- Institution
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
- Principal investigator
- Eric J Small
- Funding
- $186K
- Duration
- 1999–2028
Moonbase score
Still being scored
Abstract
Prostate Cancer Program: Summary/Abstract The overarching scientific goal of the HDFCCC Prostate Cancer (PR) Program is to use a team approach to advance the understanding of tumor biology and drive translation into more effective and targeted treatment. This is done through translational research spanning discovery bench science to clinical application and back. The PR Program also seeks to specifically address the burden of prostate cancer and disparities in outcomes among patients within the catchment area. The result will be a reduction the morbidity and mortality associated with prostate cancer and its treatments by leveraging a deep understanding of the disease at the biologic, clinical, and population levels. The PR Program approaches this mission with transdisciplinary research that is richly collaborative and translational, organized around three specific aims: (1) to discover molecular features and drivers of prostate cancer; (2) to develop and validate biomarkers and models to predict outcomes in men with prostate cancer; and (3) to develop clinical interventions to improve outcomes for men with prostate cancer.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California, San FranciscoNot yet scored
UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate Cancer
Eric J Small · $2.3M · 2024–2029
- NIH · University of California, San FranciscoNot yet scored
Administrative Core
Eric J Small · $205K · 2024–2029
- NIH · University of California, San FranciscoNot yet scored
Project 2 - Investigating Clinical and Biological Implications of a Novel Hypermethylated Subtype of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Eric J Small · $529K · 2024–2029